SG11202003398SA - Adenovirus vectors and uses thereof - Google Patents

Adenovirus vectors and uses thereof

Info

Publication number
SG11202003398SA
SG11202003398SA SG11202003398SA SG11202003398SA SG11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA
Authority
SG
Singapore
Prior art keywords
adenovirus vectors
adenovirus
vectors
Prior art date
Application number
SG11202003398SA
Other languages
English (en)
Inventor
Taco Uil
Soumitra Roy
Jort Vellinga
Selina Khan
Jerôme Custers
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202003398SA publication Critical patent/SG11202003398SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202003398SA 2017-10-31 2018-10-30 Adenovirus vectors and uses thereof SG11202003398SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199350 2017-10-31
PCT/EP2018/079719 WO2019086461A1 (fr) 2017-10-31 2018-10-30 Vecteurs d'adénovirus et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202003398SA true SG11202003398SA (en) 2020-05-28

Family

ID=60413038

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003398SA SG11202003398SA (en) 2017-10-31 2018-10-30 Adenovirus vectors and uses thereof

Country Status (13)

Country Link
US (1) US11459583B2 (fr)
EP (1) EP3704256A1 (fr)
JP (1) JP7229239B2 (fr)
KR (1) KR20200074988A (fr)
CN (1) CN111295449B (fr)
AU (1) AU2018359494A1 (fr)
BR (1) BR112020008435A2 (fr)
CA (1) CA3077630A1 (fr)
EA (1) EA202091039A1 (fr)
IL (1) IL274218A (fr)
MX (1) MX2020004490A (fr)
SG (1) SG11202003398SA (fr)
WO (1) WO2019086461A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153204A1 (fr) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Compositions d'adénovirus oncolytiques
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
EP3638302B1 (fr) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
IL299515A (en) 2020-06-29 2023-02-01 Janssen Vaccines & Prevention Bv Immune combination against respiratory syncytial virus infection
IL299459A (en) 2020-07-06 2023-02-01 Janssen Pharmaceuticals Inc Proteins fused to stabilized coronavirus spike proteins
WO2022084333A1 (fr) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Régimes de vaccin contre le vih
EP4242318A4 (fr) * 2021-01-21 2024-02-14 Cellid Co., Ltd Nouveau vecteur adénoviral ne comprenant pas d'adénovirus compétent de réplication et utilisation associée
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (fr) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (fr) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Vaccins contre le sars-cov-2
WO2023026182A1 (fr) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Vaccins anti-sars-cov-2
WO2023047349A1 (fr) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Protéines de fusion protéines de spicule de coronavirus stabilisées
WO2023047348A1 (fr) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Protéines de fusion de protéine de spicule de coronavirus stabilisées
WO2023111725A1 (fr) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Vaccins anti-sars-cov-2
WO2023110618A1 (fr) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Protéines de fusion hmpv pré-hybrides stabilisées
WO2024061759A1 (fr) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Protéines s de coronavirus stabilisées
WO2024061757A1 (fr) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Protéines f du piv1 humain en pré-fusion
WO2024074584A1 (fr) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Protéines f du piv3 sous forme pré-fusion stabilisées

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2192442C (fr) 1994-06-10 2007-09-25 Imre Kovesdi Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (fr) 1996-04-26 2007-08-14 National Research Council Of Canada Lignees de cellules complements e1 de l'adenovirus
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2001002607A1 (fr) 1999-07-06 2001-01-11 Merck & Co., Inc. Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU9456201A (en) 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
KR20040043129A (ko) 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
CA2880061C (fr) 2004-01-23 2018-03-13 Agostino Cirillo Porteurs de vaccin adenoviral de chimpanze
DE602005025512D1 (de) 2004-10-13 2011-02-03 Crucell Holland Bv Verbesserte adenovirusvektoren und deren verwendung
NZ553889A (en) * 2004-10-13 2009-11-27 Crucell Holland Bv Replication-defective adenovirus comprising a chimeric hexon protein and replaced hypervariable ragions HVR1-7
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
DK2220241T3 (en) 2007-11-28 2017-01-09 Univ Pennsylvania Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
PL2350268T3 (pl) 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
RU2604815C2 (ru) 2009-02-02 2016-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нуклеинокислотные и аминокислотные последовательности аденовируса обезьян, векторы, содержащие указанные последовательности, и их применение
JP5903045B2 (ja) 2009-07-31 2016-04-13 パックスバックス， インコーポレイテッド アデノウイルスに基づくベクター
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
EP3466440A1 (fr) 2010-04-16 2019-04-10 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Vaccins contre des filovirus basés sur des vecteurs adénoviraux de chimpanzé
WO2013016591A1 (fr) 2011-07-26 2013-01-31 Zuvachem, Inc. Isoprène synthases à efficacité élevée produites par l'ingénierie protéique
WO2013052859A2 (fr) 2011-10-05 2013-04-11 Genvec, Inc. Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos

Also Published As

Publication number Publication date
CN111295449B (zh) 2023-12-05
EP3704256A1 (fr) 2020-09-09
CA3077630A1 (fr) 2019-05-09
CN111295449A (zh) 2020-06-16
BR112020008435A2 (pt) 2020-11-17
WO2019086461A1 (fr) 2019-05-09
US20200347405A1 (en) 2020-11-05
IL274218A (en) 2020-06-30
MX2020004490A (es) 2020-08-13
AU2018359494A1 (en) 2020-04-23
JP7229239B2 (ja) 2023-02-27
JP2021500899A (ja) 2021-01-14
KR20200074988A (ko) 2020-06-25
US11459583B2 (en) 2022-10-04
EA202091039A1 (ru) 2020-08-10

Similar Documents

Publication Publication Date Title
IL274218A (en) Adenovirus vectors and their uses
ZA202002184B (en) Adenovirus and uses thereof
ZA202002191B (en) Adenovirus and uses thereof
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL273510A (en) Combined treatments and their use
IL293377A (en) hsd17b13 variants and their uses
GB201713765D0 (en) Modified adenovirus
PT3265571T (pt) Sistema de vetor múltiplo e uso do mesmo
IL268593A (en) Polypeptide variants and uses thereof
GB201715052D0 (en) Vectors
IL274220A (en) Adenovirus and its uses
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
GB201717524D0 (en) Vectors
EP3480212C0 (fr) Peptide il13ralpha2 et ses utilisations
IL275211A (en) Fast and flexible segment chains - division
GB201705927D0 (en) Vector
IL273671A (en) Cornoline variants and their use
ZA201905513B (en) Rorgamma modulators and uses thereof
ZA201905511B (en) Rorgamma modulators and uses thereof
PT3250234T (pt) Mdv1 recombinante e suas utilizações
IL274278A (en) vectors
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201711971D0 (en) Vectors
GB201706219D0 (en) Modified adenovirus
GB201712268D0 (en) Polypeptides and uses thereof